Table 2.
Ten-year probability of remaining free from BC recurrence.
| Population | Oncotype DX® test | SoC | ||||||
|---|---|---|---|---|---|---|---|---|
| RS <16 | RS 16–25 or ≤251 | RS >25 | ||||||
| ET | ET+CT | ET | ET+CT | ET | ET+CT | ET | ET+CT | |
| N0 and age < 50 years2 | 97.0% (10, 17) |
97.8% (10, 17) |
82.7% (10, 17) |
91.7% (10, 17) |
71.1% (10, 17) |
83.3% (10, 17) |
84.4% (10, 17) |
91.5% (10, 17) |
| N0 and age ≥ 50 years2 | Not applicable | Not applicable | 90.4% (10, 17) |
90.8% (10, 17) |
70.2% (10, 17) |
78.3% (10, 17) |
84.7% (10, 17) |
87.3% (10, 17) |
| N1 and age ≥ 50 years2 | Not applicable | Not applicable | 91.2% (18) |
90.6% (18) |
62.0% (25) |
75.4% (25) |
86.2% (10, 17) |
88.0% (10, 17) |
CT, chemotherapy; ET, endocrine therapy; N0, node-negative disease; N1, 1–3 invaded lymph nodes; RS, recurrence score; SoC, standard of care; BC, breast cancer.
1For premenopausal women, three RS categories were considered: <16, 16–25, and >25. For postmenopausal N0 and N1 sub-populations, only two RS categories were considered: ≤25 and >25.
2For simplification, menopause was assumed to occur at age 50.